T. Rowe Price Investment Management, Inc. Xenon Pharmaceuticals Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,503,808 shares of XENE stock, worth $58.5 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,503,808
Previous 1,439,903
4.44%
Holding current value
$58.5 Million
Previous $56.1 Million
5.46%
% of portfolio
0.04%
Previous 0.04%
Shares
4 transactions
Others Institutions Holding XENE
# of Institutions
212Shares Held
70.2MCall Options Held
88.3KPut Options Held
28.8K-
Avoro Capital Advisors LLC New York, NY5.67MShares$220 Million3.36% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.6MShares$179 Million1.77% of portfolio
-
Wellington Management Group LLP Boston, MA3.84MShares$150 Million0.03% of portfolio
-
Braidwell LP Stamford, CT2.71MShares$105 Million3.02% of portfolio
-
Commodore Capital LP New York, NY2.7MShares$105 Million9.03% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.42B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...